Poletti Samuel Jonas
Known title: Chief Strategy & M&A OfficerCIK: 0002066486
Poletti Samuel Jonas's purchase track record
Poletti Samuel Jonas has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/17/2026 | AMRZ | $118K | pending | pending | — |
| 8/8/2025 | AMRZ | $59K | +3.7% | +22.5% | +8.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMRZ | ▲ Buy | Open Market | 2,510 | $118K | 8/17/2026 | View on chart |
| AMRZ | ▲ Buy | Grant | 4,256 | $0 | 2/27/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,280 | $59K | 8/8/2025 | View on chart |
| AMRZ | ▼ Sell | Other | 2,109 | $0 | 6/23/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JP Morgan cuts Amrize price target to $48, maintains Neutral
JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.
JP Morgan cuts Amrize price target to $48, maintains Neutral. JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.